Accéder au contenu
Merck

The role of glimepiride in the treatment of type 2 diabetes mellitus.

Expert opinion on drug metabolism & toxicology (2010-01-09)
Vanessa J Briscoe, Michelle L Griffith, Stephen N Davis
RÉSUMÉ

Type 2 diabetes mellitus (T2DM) is increasingly prevalent throughout the world; controlling glycemia is an important part of preventing serious complications of diabetes. Sulfonylureas have been used in the treatment of type 2 diabetes for many years. This article reviews the pharmacological and clinical aspects of glimepiride, a second-generation sulfonylurea. Literature search was conducted in PubMed, and articles selected for relevance to pharmacology or clinical efficacy data from 1994 to 2009, with older references sought as indicated. Pharmacology of glimepiride, data regarding clinical efficacy, key comparisons to other agents and emerging concepts related to glimepiride are discussed. Therapy with glimepiride improves the relative insulin secretory deficit found in T2DM, has antihyperglycemic efficacy equal to other secretagogues with reduced potential for hypoglycemia and may have additional actions contributing to glycemic control in T2DM.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Glimepiride, ≥98% (HPLC), solid
USP
Glimepiride, United States Pharmacopeia (USP) Reference Standard
Glimepiride, European Pharmacopoeia (EP) Reference Standard
Glimepiride for system suitability, European Pharmacopoeia (EP) Reference Standard